Clinical and serological association of plasma 25-hydroxyvitamin D (25(OH)D) levels in lupus and the short-term effects of oral vitamin D supplementation.

Plain-language guide to PMID 36597127 (2023): randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 702 patients, lupus (sle).

Key Facts

PMID: 36597127
Journal: Arthritis research & therapy
Year: 2023
Study type: Randomized Controlled Trial
Authors: Kavadichanda C et al. (9 authors)
DOI: 10.1186/s13075-022-02976-7

What This Study Did, in Plain Language

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of lupus (sle) in this randomized controlled trial publication.

Data on the association of vitamin D levels and clinical phenotype and disease activity in systemic lupus erythematosus (SLE) is controversial.

Why It Was Studied

The second phase of this study was a registered randomised controlled trial CTRI/2019/06/019658 [registered on: 14/06/2019].

Who Took Part

The study group was 702 patients.

Phase I was a cross-sectional analytical study of patients from north (26.85° N) and south India (11.94° N).

Outcomes were assessed at 6 months RESULTS: Phase I included 702 patients with a mean age of 29.46 + 10.7 years.

How the Study Was Run

The design is described as randomized.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

This is a two-phase study.

Plasma 25-hydroxyvitamin-D(25(OH)D) was measured, and its association with demography, serology, disease activity, Galectin-9 and CXCL-10 was analysed.

The median plasma vitamin D was 22.83 (13.8-31.8) ng/ml.

Galactin-9 had modest correlation with SLEDAI2K but not with vitamin D levels.

In the phase II, 91 randomised to 2 groups completed 6 months.

What Was Measured

The subject headings attached to it are Cross-Sectional Studies, Vitamin D, Vitamin D Deficiency, Lupus Erythematosus, Systemic and Dietary Supplements.

Author keywords: Autoimmunity, Cholecalciferol, Interferon, SLE and SLEDAI-2KG.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 702 patients in people with lupus (sle).

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Arthritis research & therapy), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Lupus (SLE) research.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.